The third-place slot marked another return to form. Novo Nordisk’s Wegovy reclaimed the seat it held in December, backed by ...

Tenpoint Therapeutics has tasked Carol Kearney with cracking a market that confounded AbbVie. As the biotech’s newly ...

AbbVie has signed a licensing deal with Gubra A/S to develop an obesity drug, marking the North Chicago company's first foray ...

Bloomberg reports the obesity drug market is expected to reach as much as $130 billion in annual sales by 2030.

GUB014295 is a subcutaneously administered long-acting amylin agonist that also stimulates calcitonin receptors, according to ...

AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...

The licensing deal could set the US drugmaker to vie with Eli Lilly & Co. and Novo Nordisk A/S, the current leaders in a ...

AbbVie's strategic move into the obesity market through a partnership with Gubra A/S shows potential but won't impact revenue ...

North Chicago, Illinois Tuesday, March 4, 2025, 10:00 Hrs [IST] ...

AbbVie is jumping into the burgeoning obesity field, striking a license agreement with Gubra that is potentially worth more than $2 billion to the Danish drug-discovery and contract-research-services ...

AbbVie (ABBV) and Gubra announced a license agreement to develop GUB014295, a long-acting amylin analog for the treatment of obesity. Under the ...

"At AbbVie, we are focused on transforming the ... and will be eligible to receive up to $1.875 billion in development, commercial and sales milestone payments with tiered royalties on global ...